Vir Biotechnology Inc (VIR) Stock
Fundamentals
Recent news

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
VIR

Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology Q2 Earnings Call Highlights
VIR

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
VIR

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
VIR
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.60 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
VIR

Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology Q2 Earnings Call Highlights
VIR

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
VIR

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
VIR

Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology Announces Chief Financial Officer Transition
VIR

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
VIR

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
VIR

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
VIR

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
VIR

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
VIR
About Vir Biotechnology Inc
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | President, CEO & Director | 1969 |
| Ms. Vanina de Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | 1979 |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | 1947 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | — |
| Mr. Brent Sabatini CPA, M.B.A. | Senior VP, Prin. Accounting Officer, Chief Acct. Officer & Interim Prin. Financial Officer | 1975 |
| Dr. Maninder Hora Ph.D. | Executive VP & Chief Technical Operations Officer | 1954 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | — |
| Dr. Kiki Patel Pharm.D. | Head of Investor Relations | — |
| Ms. Carolyn Wang | Senior Vice President of Corporate Communications | — |
| Mr. Toby Medaris M.Sc. | Executive VP & Chief Human Resources Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.8 | +9.8 | +28.2 | -10.9 | ||||||||
| 2022 | -12.9 | -28.4 | +7.2 | -19.6 | +23.7 | -0.2 | +7.5 | -13.4 | -20.8 | +10.1 | +25.3 | -6.4 |
| 2023 | +18.6 | -21.8 | +3.0 | +8.0 | +6.0 | -8.8 | -42.8 | -11.1 | -25.1 | -11.8 | +21.8 | +3.8 |
| 2024 | -10.6 | +23.2 | -9.9 | -17.1 | +17.5 | -16.3 | +11.6 | -15.1 | -3.7 | -0.9 | -14.0 | -9.9 |
| 2025 | +43.1 | -15.9 | -18.2 | -1.0 | -18.7 | -0.6 | -0.8 | -1.8 | +14.2 | +4.6 | +14.6 | -0.7 |
| 2026 | +25.3 | +17.9 | -4.1 | +13.3 | -4.6 | +12.8 | -9.4 | +22.9 | -8.3 |



